Press release
Personal Care
October 26, 2012

TEGO® Stemlastin: Delaying chronological aging

During the chronological aging process epidermal skin stem cells become less effective, meaning that the renewing and repairing activity of the epidermis is reduced. Additionally, less and less plastic fibers are synthesized which induces a progressive loss of skin elasticity.

To reduce the signs of chronological aging Evonik launches TEGO® Stemlastin which will also be presented at the IFSCC Congress 2012. TEGO® Stemlastin protects and maintains epidermal stem cell capacity and boosts elastic fiber network. This latest active is based on a standardized extract of the micro algae Cyanidium caldarium which is produced in a natural, eco-friendly way.

The algae Cyanidium caldarium is able to survive under extreme environmental conditions. Therefore, the extract delivers a special intracellular composition of extremolytes like mineral nutrients, amino acids, algae polyphenols and is enriched in gamma amino butyric acid (GABA). Various in vitro studies have shown that TEGO® Stemlastin on the one hand protects and maintains epidermal stem cell capacity for rejuvenated skin activity. On the other hand, it boosts elastic fibers leading to highly supple skin and reduction of skin elasticity fatigue. Extended in vivo studies have confirmed that TEGO® Stemlastin leads to improved skin elasticity and diminished wrinkle formation, especially manifested in visible reduction of crow-feet.

Through its combined activity on epidermal stem cells and elastic fibers, TEGO® Stemlastin clearly retains a youthful appearance and reduces the signs of chronological aging.

Please find appropriate image data and further information on our Personal Care website:

Company Information

Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2011 more than 33,000 employees generated sales of around €14.5 billion and an operating profit (EBITDA) of about €2.8 billion.


In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.